Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Michael Cullen
AddedMar 31, 2024
UpdatedMay 31, 2026
Michael Cullen

Michael Cullen

Board Member, Panbela Therapeutics

LinkedIn

Michael Cullen's Career

Panbela Therapeutics
Panbela Therapeutics

Waconia, MN, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Michael Cullen's Career

Panbela Therapeutics
Panbela Therapeutics
Public$64.4M52011Waconia, MN, US
Board Member· Board

Leadership at Panbela Therapeutics

Dan DonovanDan DonovanBoard Member
Jeff MathiesenJeff MathiesenBoard Member
Jennifer SimpsonJennifer SimpsonCEO
Rob SargentRob SargentCo-Founder

Similar to Panbela Therapeutics

Panacela LabsPanacela LabsBuffalo, NY, USDrug Developmentest. 2011Panacela LabsBuffalo, NY, US · est. 2011

Panacela Labs: A clinical-stage biotech firm specializing in oncology and orphan drug development.

Series B · $39.9M30
Panacea PharmaceuticalsPanacea PharmaceuticalsGaithersburg, MD, USCancer Treatmentest. 1999Panacea PharmaceuticalsGaithersburg, MD, US · est. 1999

Pharmaceutical firm specializing in cancer treatment, in collaboration with top research institutions.

Public · $33.9M5
PanTher TherapeuticsPanTher TherapeuticsWatertown, MA, USCancer Treatmentest. 2016PanTher TherapeuticsWatertown, MA, US · est. 2016

PanTher Therapeutics: Revolutionizing cancer care with an effective, minimal side-effect treatment platform.

Series B · $21.3M13
PNP TherapeuticsPNP TherapeuticsBirmingham, AL, USCancer Treatmentsest. 2000PNP TherapeuticsBirmingham, AL, US · est. 2000

PNP Therapeutics: Innovating proprietary technology for effective cancer treatments.

Angel · $2.6M5

People Similar to Michael Cullen

Dhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoMason YeoMason YeoBoard Member · KakaoBrian KimBrian KimCo-Founder · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoBrian KimBrian KimBoard Member · KakaoSong Ji-Ho 'DeanSong Ji-Ho 'DeanBoard Member · KakaoSean JohSean JohBoard Member · Kakao